Switch theme
Sign up to access all valuation multiples
Advicenne SA is a late-stage biopharmaceutical company. The company is engaged in the development of paediatric friendly therapeutics for the treatment of orphan renal diseases and niche neurology indications. Its goal is to improve the lives of patients from early childhood through adulthood.
2007
26
LTM Revenue $6.0M
LTM EBITDA -$4.5M
$37.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Advicenne has a last 12-month revenue (LTM) of $6.0M and a last 12-month EBITDA of -$4.5M.
In the most recent fiscal year, Advicenne achieved revenue of $5.9M and an EBITDA of -$7.4M.
Advicenne expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Advicenne valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.0M | XXX | $5.9M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | -$1.4M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | -24% | XXX | XXX | XXX |
| EBITDA | -$4.5M | XXX | -$7.4M | XXX | XXX | XXX |
| EBITDA Margin | -75% | XXX | -127% | XXX | XXX | XXX |
| EBIT | -$5.7M | XXX | -$10.7M | XXX | XXX | XXX |
| EBIT Margin | -95% | XXX | -182% | XXX | XXX | XXX |
| Net Profit | -$6.8M | XXX | -$7.6M | XXX | XXX | XXX |
| Net Margin | -113% | XXX | -130% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $17.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Advicenne's stock price is EUR 1 (or $2).
Advicenne has current market cap of EUR 16.8M (or $19.8M), and EV of EUR 31.8M (or $37.4M).
See Advicenne trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $37.4M | $19.8M | XXX | XXX | XXX | XXX | $-0.52 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Advicenne has market cap of $19.8M and EV of $37.4M.
Advicenne's trades at 6.4x EV/Revenue multiple, and -5.0x EV/EBITDA.
Equity research analysts estimate Advicenne's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Advicenne has a P/E ratio of -2.9x.
See valuation multiples for Advicenne and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.8M | XXX | $19.8M | XXX | XXX | XXX |
| EV (current) | $37.4M | XXX | $37.4M | XXX | XXX | XXX |
| EV/Revenue | 6.2x | XXX | 6.4x | XXX | XXX | XXX |
| EV/EBITDA | -8.3x | XXX | -5.0x | XXX | XXX | XXX |
| EV/EBIT | -6.6x | XXX | -3.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.9x | XXX | -2.6x | XXX | XXX | XXX |
| EV/FCF | -8.6x | XXX | -37.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAdvicenne's last 12 month revenue growth is 30%
Advicenne's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Advicenne's rule of 40 is -168% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Advicenne's rule of X is -1% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Advicenne and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 30% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Margin | -75% | XXX | -127% | XXX | XXX | XXX |
| EBITDA Growth | -54% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -168% | XXX | -97% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 159% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Advicenne acquired XXX companies to date.
Last acquisition by Advicenne was XXXXXXXX, XXXXX XXXXX XXXXXX . Advicenne acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Advicenne founded? | Advicenne was founded in 2007. |
| Where is Advicenne headquartered? | Advicenne is headquartered in France. |
| How many employees does Advicenne have? | As of today, Advicenne has 26 employees. |
| Who is the CEO of Advicenne? | Advicenne's CEO is Mr. Didier Laurens. |
| Is Advicenne publicy listed? | Yes, Advicenne is a public company listed on PAR. |
| What is the stock symbol of Advicenne? | Advicenne trades under ALDVI ticker. |
| When did Advicenne go public? | Advicenne went public in 2017. |
| Who are competitors of Advicenne? | Similar companies to Advicenne include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform. |
| What is the current market cap of Advicenne? | Advicenne's current market cap is $19.8M |
| What is the current revenue of Advicenne? | Advicenne's last 12 months revenue is $6.0M. |
| What is the current revenue growth of Advicenne? | Advicenne revenue growth (NTM/LTM) is 30%. |
| What is the current EV/Revenue multiple of Advicenne? | Current revenue multiple of Advicenne is 6.2x. |
| Is Advicenne profitable? | Yes, Advicenne is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Advicenne? | Advicenne's last 12 months EBITDA is -$4.5M. |
| What is Advicenne's EBITDA margin? | Advicenne's last 12 months EBITDA margin is -75%. |
| What is the current EV/EBITDA multiple of Advicenne? | Current EBITDA multiple of Advicenne is -8.3x. |
| What is the current FCF of Advicenne? | Advicenne's last 12 months FCF is -$4.3M. |
| What is Advicenne's FCF margin? | Advicenne's last 12 months FCF margin is -72%. |
| What is the current EV/FCF multiple of Advicenne? | Current FCF multiple of Advicenne is -8.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
